Related Experiment Video
Updated: Aug 25, 2026

Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction
Published on: October 11, 2024
Recombinant adeno-associated virus as delivery vector for gene therapy--a review
1Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. ylu@jhmi.edu
Abstract:
Recombinant adeno-associated virus (rAAV) is one of the most promising delivery vectors for gene therapy, due to its nonpathogenic property, nonimmunogenecity to host, and broad cell and tissue tropisms. This article summarizes the biological characteristics of AAV; the procedures to prepare, purify, and characterize the rAAV for gene therapy applications; and some of the clinical trials utilizing rAAV as delivery vehicles. Also discussed are the current efforts to modify rAAV to change its tropism, the application of different promoters to accommodate specific transgene expression, and the strategy to expand its capacity.

